CLOUD-R HAE registry for hereditary angioedema patients
Part of Heart & circulation, Immune system & allergy, Skin clinical trials.
This registry study collects information from people with hereditary angioedema (swelling episodes) and related types, with or without a C1-related blood condition. It may help doctors better understand different patterns of swelling and improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have swelling episodes (angioedema) without hives or wheals
- You may have hereditary angioedema, with or without a C1-related deficiency
- You (or your parent/legal guardian if under 18) can provide signed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects blood samples (and optional skin samples) from people with angioedema to learn more about the condition and find better ways to diagnose and treat it. If you join, you may help scientists understand angioedema better.
This study checks if a blood test measuring C1-inhibitor function can help diagnose hereditary angioedema (HAE), a rare condition that causes painful swelling episodes. If you or a close family member have had swelling without rash or itching that lasts 1-5 days and doesn't get better with allergy meds, this trial may be for you.
This study looks for genetic changes that may explain hereditary angioedema (HAE) and how C1 inhibitor (C1INH) works. Your participation may help researchers better understand what causes symptoms and who is affected.
This study is an extension trial of an oral medicine (PHA-022121) for treating acute attacks in people with hereditary angioedema (HAE), especially HAE type III (HAE-nC1INH). It checks whether continuing this oral treatment can safely help manage attacks after you’ve taken it before.
This study looks at how people with hereditary angioedema (HAE) are diagnosed and treated in Egypt. It may help doctors better understand and care for this condition.
This trial tests a plasma-derived C1 esterase inhibitor to treat and prevent acute attacks in people with hereditary angioedema (HAE) types 1 or 2. It aims to see if the medicine can quickly relieve swelling episodes and reduce their frequency.
Hear when a new Angioedema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.